 Durga Udayakumar, Ph.D.
| Title | Instructor in Dermatology |
|---|
| Institution | Massachusetts General Hospital |
|---|
| Department | Dermatology |
|---|
| Address | Massachusetts General Hospital
Wellman Ctr - Edwards 2
55 Fruit St
Boston MA 02114
|
|---|
|
|
|
 Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE. RhoB Differentially Controls Akt Function in Tumor Cells and Stromal Endothelial Cells during Breast Tumorigenesis. Cancer Res. 2013 Jan 1; 73(1):50-61.
-
Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. EphA2 is a critical oncogene in melanoma. Oncogene. 2011 Dec 15; 30(50):4921-9.
-
Udayakumar D, Mahato B, Gabree M, Tsao H. Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg. 2010 Sep; 29(3):190-5.
-
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1; 70(13):5213-9.
-
Yang G, Thieu K, Tsai KY, Piris A, Udayakumar D, Njauw CN, Ramoni MF, Tsao H. Dynamic gene expression analysis links melanocyte growth arrest with nevogenesis. Cancer Res. 2009 Dec 1; 69(23):9029-37.
-
Udayakumar D, Tsao H. Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med. 2009; 1(10):95.
-
Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am. 2009 Jun; 23(3):415-29, vii.
-
Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15; 68(22):9551-7.
-
Bladen CL, Udayakumar D, Takeda Y, Dynan WS. Identification of the polypyrimidine tract binding protein-associated splicing factor.p54(nrb) complex as a candidate DNA double-strand break rejoining factor. J Biol Chem. 2005 Feb 18; 280(7):5205-10.
-
Lee KJ, Jovanovic M, Udayakumar D, Bladen CL, Dynan WS. Identification of DNA-PKcs phosphorylation sites in XRCC4 and effects of mutations at these sites on DNA end joining in a cell-free system. DNA Repair (Amst). 2004 Mar 4; 3(3):267-76.
-
Udayakumar D, Bladen CL, Hudson FZ, Dynan WS. Distinct pathways of nonhomologous end joining that are differentially regulated by DNA-dependent protein kinase-mediated phosphorylation. J Biol Chem. 2003 Oct 24; 278(43):41631-5.
This graph shows the total number of publications by year.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
|
Udayakumar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|